Insider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $214,899.72 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 45,147 shares of CAMP4 Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $4.76, for a total transaction of $214,899.72. Following the completion of the sale, the director owned 2,579,998 shares of the company’s stock, valued at $12,280,790.48. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $4.48. 126,663 shares of the company’s stock traded hands, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a 52 week low of $1.41 and a 52 week high of $7.75. The company’s 50 day simple moving average is $4.11 and its 200 day simple moving average is $4.33. The company has a market cap of $281.12 million, a price-to-earnings ratio of -1.93 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The business had revenue of $1.78 million for the quarter. As a group, equities research analysts predict that CAMP4 Therapeutics Corporation will post -0.59 earnings per share for the current year.

Institutional Trading of CAMP4 Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bridgeway Capital Management LLC bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics during the fourth quarter worth about $61,000. Jefferies Financial Group Inc. bought a new position in CAMP4 Therapeutics during the fourth quarter valued at about $70,000. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $78,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at $115,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.